METFORMIN - NADEZhNYY PARTNER V LEChENII PATsIENTOV S SAKhARNYM DIABETOM 2 TIPA


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

In the treatment of type 2 diabetes mellitus (DM2), impact on pathogenetic key link in development of the disease, insulin resistance, plays an important role. For this purpose, biguanides, particularly metformin, are used in medical practice more than 50 years. The review summarizes data on the role of metformin in the treatment of DM2. Various effects of drug on glycemic control, the impact on the cardiovascular system, lipid metabolism, hemostasis, antioxidant system as well as the experience and results of the application in obstetrics and gynecology, are discussed. Particular attention is paid to the anti-cancer effects of metformin. One of the representatives of the metformin, Glucophage, is considered.

全文:

受限制的访问

参考

  1. Godarzi M.O., Brier-Ash M. Metformin revisited: revaluation of its properties and the pharmacopoeia of modern sntidiabetic agents. Diabetes Obes. Metab. 2005; 5: 654-65.
  2. Bailey C.J., Turner R.C. Metformin. N. Engl. J. Med. 1996; 334: 574-79.
  3. UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352: 837-53.
  4. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012; 35.
  5. Zhou G., Myers R., Li Y., et al. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 2001; 108: 1167-74.
  6. Hardie D.G., Ross F.A., Hawley S.A. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat. Rev. Mol. Cell Biol. 2012; 13: 251-62.
  7. Shaw R.J., Lamia K.A., Vasquez D. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science. 2005; 310: 1642-46.
  8. El-Mir M.Y., Nogueira V., Fontaine E. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J. Biol. Chem. 2000; 275; 223-28.
  9. Genuth S. The UKPDS and its global impact. Diabet Med. 2008; 25(2): 57-62.
  10. Chau-Van C., Gamba M., Salvi R., et al. Metformin inhibits adenosine 5'-monophosphate-activated kinase activation and prevents increases in neuropeptide Y expression in cultured hypothalamic neurons. Endocrinology. 2007; 148(2): 507-11.
  11. Glueck C.J., Fontaine R.N., Wang P. Metformin reduces weight, centripetalobesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30. Metabolism. 2001; 50: 856-61.
  12. Eleftheriadou I., Grigoropoulou P., Katsilambros N., Tentolouris N. The effects of medications used for the management of diabetes and obesity on postprandial lipid metabolism. Curr. Diabet. Rev. 2008; 4: 340-56.
  13. Erdmann E. Microalbuminuria as a marker of cardiovascular risk in patients with type 2 diabetes. Int. J. Cardiol. 2006; 107: 147-53.
  14. Aguayo Rojas L.B., Gomes M.B. Metformin: an old but still the best treatment for type 2 diabetes. Diabetology & Metabolic Syndrome. 2013; 5: 6.
  15. Мкртумян А.М., Бирюкова Е.В. Метформин -единственный бигуанид с широким спектром действия, рекомендованный IDF как препарат первого ряда выбора. Русский медицинский журнал. 2006; 14(27): 1991-96.
  16. Isoda K., Young J., Zirlik A. Metformin inhibits Proinflammatory Responses and Nuclear Factor in Human Vascular Wall Cells. Arterioscler. Thromb. Vasc. Biol. 2006; 26: 611-17.
  17. The Diabetes Prevention Program Research Group Intensive: Lifestyle Intervention or Metformin on Inflammation and Coagulation in Participants With Impaired Glucose Tolerance. Diabetes. 2005; 54(5): 1566-72.
  18. Faure P., Rossini E., Wiernsperger N. An insulin sensitizer improves the free radical defense system potential and insulin sensitivity in high fructose-fed rats. Diabetes. 1999; 48: 353-57.
  19. Beisswenger P., Rugiero-Lopez D. Metformin inhibition of glycation processes. Diabetes Metab. 2003; 29(6S): 95-103.
  20. Anedda A., Rial E., Gonzalez B. Metformin induces oxidative stress in white adipocytes and raises uncoupling proten levels. J. Endocrinol. 2008; 199: 33-40.
  21. Zheng Z., Chen H., Li J., et al. Sirtuin 1-mediated cellular metabolic memory of high glucose via the LKB1/AMPK/ROS pathway and therapeutic effects of metformin. Diabetes. 2012; 61(1): 217-28.
  22. Lily M., Godwin M. Treating prediabetes with metformin systematic review and meta-analysis. Can. Fam. Physician. 2009; 55: 363-69.
  23. Desilets A.R., Dhakal-Karki S., Dunican K.C. Role of metformin for weight management in patients without type 2 diabetes. Ann. Pharmacother. 2008; 42: 817-26.
  24. Kusaka I., Nagasaka S., Horie H., Ishibashi S. Metformin, but not pioglitazone, decreases postchallenge plasma ghrelin levels in type 2 diabetic patients: a possible role in weight stability? Diabetes Obes. Metab. 2008; 10: 1039-46.
  25. Mannucci E., Ognibene A., Cremasco F. Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care. 2001; 24: 489-94.
  26. Boussageon R., Supper I., Bejan-Angoulvant T. Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. PLoSMed. 2012; 9(4): e1001204.
  27. MacDonald M.R., Petrie M.C., Hawkins N.M. Diabetes, left ventricular systolic dysfunction, and chronic heart failure. Eur. Heart J. 2008; 10: 1224-40.
  28. Hulisz D.T., Bonfiglio M.F., Murray R.D. Metformin-associated lactic acidosis. J. Am. Board. Fam. Pract. 1998; 11: 233-36.
  29. Papanas N., Maltezos E., Mikhailidis D.P. Metformin and heart failure: never say never again. Expert Opin. Pharmacother. 2012; 1: 1-8.
  30. Rachmani R., Slavachevski I., Levi Z., Zadok B., Kedar Y., Ravid M. Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contraindications. Eur. J. Intern. Med. 2002; 13: 428-33.
  31. Chen S.Q., Liu Q., Sun H., Tang L., Deng J.C. Effects of metformin on fatty liver in insulin-resistant rats. ZhonghuaGanZang Bing ZaZhi. 2005; 13(12): 915-18.
  32. Diamanti-Kandarakis E., Christakou C.D., Kandaraki E., Economou F.N. Metformin: an old medication of new fation: evolving new molecular mechanism and clinical implications in polycystic ovary syndrome. Eur. J. Endocrinol. 2010; 162(2): 193-212.
  33. Glueck C.J., Goldenberg N.,Wang P., Loftspring M., Sherman A. Metformin during pregnancy reduces insulin, insulin resistance, insulin secretion, weight, testosterone and development of gestational diabetes: prospective longitudinal assessment of women with polycystic ovary syndrome from preconception throughout pregnancy. Human Reproduction. 2004; 19: 3: 510-21.
  34. Genazzani A.D., Ricchieri F., Lanzoni C. Use of metformin in the treatment of polycystic ovary syndrome. Womens Health (LondEngl). 2010; 6(4): 577-93.
  35. Kovo M., Weissman A., Gur D. et al. Neonatal outcome in polycystic ovarian syndrome patients treated with metformin during pregnancy. J. Matern. Fetal. Neonat. Med. 2006; 19: 415-19.
  36. Dowling R., Goodwin P.J., Stambolic V. Understanding the benefit of metformin use in cancer treatment. BMC Medicine. 2011; 9: 33.
  37. Li D., Yeung S.J., Hassan M.M., Konopleva M., Abbruzzese J.L. Anti-diabetic therapies affect risk of pancreatic cancer. Gastroenterology. 2009; 137(2): 482-88.
  38. Donadon V., Balbi M., Valent F., Avogaro A. Glycated hemoglobin and antidiabetic strategies as risk factors for hepatocellular carcinoma. World J. Gastroenterol. 2010; 16(24): 3025-32.
  39. Landman G.W., Kleefstra N., van Hateren K.J. Metformin associated with lower cancer mortality in type 2 diabetes ZODIAC-16. Diabetes Care. 2010; 33: 322-26.
  40. Lee J.H., Kim T.I., Jeon S.M. The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus. Int. J. Cancer. 2011; 12: 1-24.
  41. Libby G., Donnelly L.A., Donnan P.T. New users of metformin area at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care. 2009; 32: 1620-25.
  42. Hosono K., Endo H., Takahashi H., Sugiyama M., Sakai E., et al. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev. Res. (Phila). 2010; 3: 1077-83.
  43. Niraula S., Stambolic V., Dowling R.J.O., et al. Clinical and biologic effects of metformin in early stage breast cancer. Cancer Res. 2010; 70(24): 104s.
  44. Hadad S.M., Dewar J.A., Elseedawy E., et al. Gene Signature of metformin actions on primary breast cancer within a window of opportunity randomized clinical trial. J. Clin. Oncol. 2010; 28: 560.
  45. Hirsh H., Iliopoulos D., Tsichlis P., Stuh K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 2009; 69(19): 7507-11.
  46. Salpeter S.R., Greyber E., Pasternak G.A., Salpeter E.E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010; 1: CD002967.
  47. Tahrani A.A., Varghese G.I., Scarpello J.H., Hanna F.W.F. Metformin, heart failure and lactic acidosis: is Metformin absolutely contraindicated? BMJ. 2007; 355: 508-12.
  48. Bauman W.A., Shaw S., Jayatilleke E. Increased intake of calcium reverses vitamin B12 malabsorption induced by metformin. Diabetes Care. 2000; 23: 1227-31.
  49. Jager J., Kooy A., Lehert P., Wulffel M. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomized placebo controlled trial. BMJ.2010; 340: c2181.
  50. Wei Ting R.Z., Szeto C.C., Chan M., Ma K. Risk Factors of Vitamin B12 Deficiency in Patients Receiving Metformin. Arch Intern. Med. 2006; 166: 1975-79.
  51. Desilets D.J., Shorr A.F., Moran K.A., Holtzmuller K.C. Cholestatic jaundice associated with the use of metformin. Am. J. Gastroenterol. 2001; 96: 2257-58.
  52. Kashyap A.S., Kashyap S. Haemolytic anaemia due to metformin. Postgrad Med. J. 2000; 76: 125-26.
  53. Blonde L., et al. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study. Curr. Med. Res. Opinm. 2004; 20(4): 565-72.

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##